MiNK Therapeutics, Inc. (INKT)
| Market Cap | 41.17M -20.4% |
| Revenue (ttm) | 200,000 |
| Net Income | -11.02M |
| EPS | -2.25 |
| Shares Out | 5.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,030 |
| Open | 8.32 |
| Previous Close | 8.61 |
| Day's Range | 7.76 - 8.60 |
| 52-Week Range | 7.76 - 16.93 |
| Beta | 0.44 |
| Analysts | Strong Buy |
| Price Target | 44.00 (+448.63%) |
| Earnings Date | Nov 11, 2026 |
About INKT
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients wit... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for INKT stock is "Strong Buy." The 12-month stock price target is $44.0, which is an increase of 448.63% from the latest price.
News
MiNK Therapeutics Earnings Call Transcript: Q3 2026
A randomized 90-patient phase II ARDS trial is underway, with preliminary findings targeted for H2 2026. Q1 2026 net loss was $2.7 million, and cash of $9.5 million supported at least 12 months of planned runway.
MiNK Therapeutics Earnings release: Q3 2026
MiNK Therapeutics released its Q3 2026 earnings on November 11, 2026, summarizing the period's financial results.
MiNK Therapeutics Quarterly report: Q3 2026
MiNK Therapeutics has published its Q3 2026 quarterly earnings report on November 11, 2026.
MiNK Therapeutics reports Q3 EPS (50c), consensus (66c)
Reports Q3 revenue $200,000, consensus $75,000. āWe now have a randomized trial running in critical illness, multiple clinical programs enrolling and a path toward pivotal development. This quarter, p...
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering unmodified, off-the-shelf allogeneic invariant natural killer ...
MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies, t...
MiNK Therapeutics assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of MiNK Therapeutics (INKT) with a Buy rating and $38 price target MiNK is a clinical stage biotech developing allogeneic, off-the-shelf invariant natural killer T cel...
MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the Socie...
MiNK Therapeutics price target raised to $50 from $43 at B. Riley
B. Riley analyst Mayank Mamtani raised the firmās price target on MiNK Therapeutics (INKT) to $50 from $43 and keeps a Buy rating on the shares. MiNKās agenT-797 showed promisingā¦
MiNK Therapeutics management to meet virtually with B. Riley
Virtual Meeting to be held on October 22 hosted by B. Riley.
MiNK Therapeutics management to meet virtually with B. Riley
Virtual Meeting to be held on October 19 hosted by B. Riley.
MiNK Therapeutics management to meet virtually with B. Riley
Virtual Meeting to be held on October 13-14 hosted by B. Riley.
MiNK Therapeutics Slides: Corporate presentation
MiNK Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 7, 2026.
MiNK Therapeutics to present data on cancer research at SITC 2026
MiNK Therapeutics (INKT) announced two poster presentations at the Society for Immunotherapy of Cancer, SITC, 41st Annual Meeting. The presentations address two distinct areas of cancer research: tumo...
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc.Ā (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapi...
MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy
MiNK Therapeutics (INKT) announced that its clinical-stage agenT-797 iNKT platform has been selected as a therapeutic cell system within an Advanced Research Projects Agency for Health-funded team dev...
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature
MiNK Therapeutics Earnings Call Transcript: Q2 2026
Advanced a phase II ARDS trial with early positive data and no major safety issues, expanded a paid access program to Brazil, and maintained financial discipline with a narrowed net loss. Enrollment continues in Ukraine and U.S. sites, with preliminary data expected in early 2027.
MiNK Therapeutics Earnings release: Q2 2026
MiNK Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
MiNK Therapeutics Quarterly report: Q2 2026
MiNK Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (iNKT) cel...
MiNK Therapeutics presents early observations from Phase 2 agenT-797 trial
MiNK Therapeutics (INKT) announced initial observations from patients treated with agenT-797 in its ongoing Phase 2 study in patients with severe hypoxemic pneumonia. The observations were presented a...
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to...
MiNK Therapeutics Transcript: AGM 2026
The meeting approved the election of directors and auditor, confirmed a quorum, and outlined a strategy focused on immune restoration across diseases. Key initiatives include advancing clinical trials in ARDS, expanding global access, and securing external funding for new therapies.
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc.Ā (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) ce...